Until its sudden dorr cloosing inSpring 2016, Atherotech Inc had been a privately held medical diagnostic company and specialty reference laboratory . The firm had developed and marketed the Vertical Auto Profile (VAP(tm)) Test, a next-generation cholesterol test that improves the detection rate of those at risk for heart disease. The company provided testing services to Physicians, Hospitals, Clinics, and other Laboratories throughout the United States. Late in 2010, Atherotech was acquired by Behrman Capital, a New York private equity firm. With Atherotech having a license to a proprietary direct measurement test for cholesterol, the acquiring firm had plans focuses on improving the early detection of cardiovascular disease. Following the acquisition, the small firm shifted into high growth mode with major increases in propftiability. Various business decisions made by the private equity holders did not play out at planned and inthe midst of the financial downturn, the US Dept of Justice brought suit against management. Subsequently, the firm also fell under much stricter review; insurance reimbursement shifted, layoff =s began and finally the decison to close down operations with the simaltaneous annoubcement of layoff of all 225 employees.
